{"id":"NCT02634788","sponsor":"INSYS Therapeutics Inc","briefTitle":"Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain","officialTitle":"A Phase 3, Randomized, Double Blind, Multiple Dose, Parallel Group, Placebo Controlled Study of Buprenorphine Sublingual Spray (0.5 mg TID, 0.25 mg TID, and 0.125 mg TID) for the Treatment of Moderate to Severe Pain","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-01-29","primaryCompletion":"2016-06-24","completion":"2016-06-24","firstPosted":"2015-12-18","resultsPosted":"2017-08-14","lastUpdate":"2017-08-14"},"enrollment":322,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pain"],"interventions":[{"type":"DRUG","name":"Buprenorphine","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Buprenorphine 0.5 mg TID","type":"EXPERIMENTAL"},{"label":"Buprenorphine 0.25 mg TID","type":"EXPERIMENTAL"},{"label":"Buprenorphine 0.125 mg TID","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of this trial is to evaluate analgesic efficacy of Buprenorphine Sublingual (under the tongue) Spray compared with placebo in participants with postoperative pain after bunionectomy.","primaryOutcome":{"measure":"Numeric Rating Scale (NRS) Summed Pain Intensity Difference (SPID) Over 0 to 48 Hours After Time 0 (NRS SPID-48)","timeFrame":"Baseline and 0 to 48 hours after Time 0","effectByArm":[{"arm":"Placebo","deltaMin":89.4,"sd":10.109},{"arm":"Buprenorphine 0.5 mg TID","deltaMin":171.33,"sd":10.316},{"arm":"Buprenorphine 0.25 mg TID","deltaMin":125.58,"sd":10.101},{"arm":"Buprenorphine 0.125 mg TID","deltaMin":124.85,"sd":9.944}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"0.0108"},{"comp":"OG000 vs OG003","p":"0.0120"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":2},"locations":{"siteCount":4,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":79},"commonTop":["Nausea","Vomiting","Dizziness","Headache","Oxygen saturation decreased"]}}